scholarly journals MA 07.06 Detection of Mechanisms of Resistance to ALK Inhibitors in Routine Practice: A Retrospective Study

2017 ◽  
Vol 12 (11) ◽  
pp. S1828
Author(s):  
P. Jamme ◽  
C. Descarpentries ◽  
M. Wislez ◽  
E. Dansin ◽  
V. Grégoire ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Routine Practice ◽  
Mechanisms Of Resistance ◽  
Alk Inhibitors

scholarly journals Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice

Cells ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 168
Author(s):  
Paul Hofman
Keyword(s):  
Tumor Tissue ◽  
Tumor Response ◽  
Routine Practice ◽  
Mechanisms Of Resistance ◽  
Liquid Biopsies ◽  
Genomic Alterations ◽  
Alk Inhibitors ◽  
Initial Tumor ◽  
Biological Sampling

The survival of most patients with advanced stage non-small cell lung cancer is prolonged by several months when they are treated with first- and next-generation inhibitors targeting ALK rearrangements, but resistance inevitably emerges. Some of the mechanisms of resistance are sensitive to novel ALK inhibitors but after an initial tumor response, more or less long-term resistance sets in. Therefore, to adapt treatment it is necessary to repeat biological sampling over time to look for different mechanisms of resistance. To this aim it is essential to obtain liquid and/or tissue biopsies to detect therapeutic targets, in particular for the analysis of different genomic alterations. This review discusses the mechanisms of resistance to therapeutics targeting genomic alterations in ALK as well as the advantages and the limitations of liquid biopsies for their identification.

scholarly journals Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice

2019 ◽  
Vol 20 (4) ◽  
pp. 297-304.e1 ◽  
Author(s):  
Philippe Jamme ◽  
Clotilde Descarpentries ◽  
Radj Gervais ◽  
Eric Dansin ◽  
Marie Wislez ◽  
...  
Keyword(s):  
Routine Practice ◽  
Mechanisms Of Resistance ◽  
Alk Inhibitors

scholarly journals P26 Helicobacter pylori culture in routine practice: A paediatric retrospective study

2021 ◽  
Author(s):  
Rime Hicham ◽  
Mary Ann Ritchie ◽  
William Ennis ◽  
Margaret Murray ◽  
Pamela Saunders ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Retrospective Study ◽  
Routine Practice

scholarly journals Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

2016 ◽  
Vol 6 (10) ◽  
pp. 1118-1133 ◽  
Author(s):  
Justin F. Gainor ◽  
Leila Dardaei ◽  
Satoshi Yoda ◽  
Luc Friboulet ◽  
Ignaty Leshchiner ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Molecular Mechanisms ◽  
Second Generation ◽  
Mechanisms Of Resistance ◽  
Alk Inhibitors ◽  
First And Second Generation

scholarly journals NGS‐based liquid‐biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step towards personalized NSCLC treatment

2021 ◽  
Author(s):  
Estela Sánchez‐Herrero ◽  
Roberto Serna‐Blasco ◽  
Vadym Ivanchuk ◽  
Rosario García‐Campelo ◽  
Manuel Dómine Gómez ◽  
...  
Keyword(s):  
Liquid Biopsy ◽  
Mechanisms Of Resistance ◽  
Alk Inhibitors

Vinflunine (VFL) as second-line chemotherapy for patients with transitional cell carcinoma of the urothelium (TCCU): A multicenter retrospective study.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15620-e15620
Author(s):  
Guillermo De Velasco ◽  
Isabel Chirivella ◽  
Belen Gonzalez-Grajera ◽  
Ovidio Fernandez Calvo ◽  
Alvaro Pinto ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Standard Dose ◽  
Objective Response ◽  
Transitional Cell ◽  
Active Agent ◽  
Progression Free Survival ◽  
Complete Response ◽  
Routine Practice ◽  
Second Line ◽  
Platinum Based Chemotherapy

e15620 Background: VFL is the standard chemotherapy in second-line advanced TCCU in Europe (EMA approval 21/09/2009). We set up a multicenter retrospective study to evaluate the efficacy and toxicity of VFL in patients (pts) with advanced TCCU after platinum failure within the framework of routine practice. Methods: Descriptive and retrospective study in pts who had demonstrated prior progression to a platinum-containing chemotherapy regimen at 7 centers. VFL standard dose (280-320/m2 every three weeks) was administered until progression or unacceptable toxicity. Objective response was evaluated according to RECIST criteria v.1.1. Results: Between April 2010 and December 2012, a total of 45 pts with median age of 68 years (range 47-83) were analyzed. Main characteristics: ECOG 0-1-2 in 7pts (15.6%), 33pts (73.3%), 5pts (11.1%). Mean creatinine clearance was 59 ml/min. Primary sites of disease were bladder 39pts (86.7%), renal pelvis 5pts (11.1%) and prostatic urethra 1pt (2.2%). All pts had previously received platinum-based chemotherapy as a first-line treatment (cisplatin in 45% of pts). Metastatic locations were: 27pts (60%) lymph nodes, 18pts (40%) lung, 13pts (29%) bone and 10pts (22%) liver. The median number of cycles of VFL was 5 (1-18). All pts were assessed for response, one (2.2%) patient presented complete response (CR), 11pts (24.4%) partial response (PR), 18pts (40%) stable disease (SD) and 15pts (33.4%) progressive disease (PD). Median progression-free survival was 4 months (95% CI, 2.2-5.7). Median overall survival (OS) was 11 months (95% CI, 3.5-18). OS at 6 months was 45%. Liver metastasis was the main prognostic factor for OS (p=0.04). Grade 3/4 adverse events included neutropenia 6pts (13%), constipation 4pts (9%), abdominal pain 4pts (9%) and nausea/vomiting 3pts (6%). Conclusions: This retrospective analysis confirm VFL as an active agent in pts progressing after platinum-based combination for advanced TCCU in a daily clinical practice in Spain. As ESMO (Bellmunt J, 2011) and Spanish (Castellano D, 2012) guidelines recommend vinflunine, it should be offered in this setting or alternatively, treatment within a clinical trial.

Sign in / Sign up

Export Citation Format

Share Document